A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer

Trial Profile

A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer

Suspended
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2015

At a glance

  • Drugs Binimetinib (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Biliary cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jul 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.
    • 06 Jul 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017, as reported by ClinicalTrials.gov.
    • 06 Jul 2015 Planned initiation date changed from 1 Jun 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top